KR102731476B1 - 항-tigit 항체 - Google Patents

항-tigit 항체 Download PDF

Info

Publication number
KR102731476B1
KR102731476B1 KR1020207005664A KR20207005664A KR102731476B1 KR 102731476 B1 KR102731476 B1 KR 102731476B1 KR 1020207005664 A KR1020207005664 A KR 1020207005664A KR 20207005664 A KR20207005664 A KR 20207005664A KR 102731476 B1 KR102731476 B1 KR 102731476B1
Authority
KR
South Korea
Prior art keywords
tigit
antibody
cells
seq
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207005664A
Other languages
English (en)
Korean (ko)
Other versions
KR20200100589A (ko
Inventor
안토니 쿠퍼
크리스토페 쿠에바
소피 데니에스
카테리네 후프드
줄리아 쿠엔데
그레고리 드리에센스
플로렌스 람볼레즈
Original Assignee
아이테오스 벨지움 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BE2017/5535A external-priority patent/BE1025333B1/fr
Application filed by 아이테오스 벨지움 에스에이 filed Critical 아이테오스 벨지움 에스에이
Priority claimed from PCT/US2018/043968 external-priority patent/WO2019023504A1/en
Publication of KR20200100589A publication Critical patent/KR20200100589A/ko
Application granted granted Critical
Publication of KR102731476B1 publication Critical patent/KR102731476B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207005664A 2017-07-27 2018-07-26 항-tigit 항체 Active KR102731476B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762606159P 2017-07-27 2017-07-27
US62/606,159 2017-07-27
BE2017/5535A BE1025333B1 (fr) 2017-07-27 2017-07-31 Anticorps anti-tigit
EP17184102.6 2017-07-31
EP17184102 2017-07-31
BE20175535 2017-07-31
US201862660640P 2018-04-20 2018-04-20
US62/660,640 2018-04-20
PCT/US2018/043968 WO2019023504A1 (en) 2017-07-27 2018-07-26 ANTI-TIGIT ANTIBODIES

Publications (2)

Publication Number Publication Date
KR20200100589A KR20200100589A (ko) 2020-08-26
KR102731476B1 true KR102731476B1 (ko) 2024-11-18

Family

ID=65896429

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005664A Active KR102731476B1 (ko) 2017-07-27 2018-07-26 항-tigit 항체

Country Status (14)

Country Link
US (5) US20200407445A1 (enExample)
EP (2) EP3719040A1 (enExample)
JP (2) JP7366897B2 (enExample)
KR (1) KR102731476B1 (enExample)
CN (2) CN110997720B (enExample)
AR (1) AR112768A1 (enExample)
AU (1) AU2018306463B2 (enExample)
BR (1) BR112020001499A2 (enExample)
CA (1) CA3070791A1 (enExample)
ES (1) ES2812236T3 (enExample)
IL (1) IL272227B2 (enExample)
MX (2) MX2020000960A (enExample)
SG (1) SG11202000660QA (enExample)
TW (1) TWI812632B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
AU2019272384A1 (en) 2018-05-23 2021-01-07 Beigene, Ltd. Anti-OX40 antibodies and methods of use
KR102776112B1 (ko) 2018-09-11 2025-03-11 아이테오스 벨지움 에스에이 A2a 억제제로서 싸이오카바메이트 유도체, 이의 약학 조성물 및 항암제와의 조합물
CN113993894B (zh) * 2019-01-07 2024-08-02 Iteos比利时公司 抗tigit抗体
TWI760751B (zh) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
BR112021022171A2 (pt) * 2019-06-13 2021-12-21 Green Cross Corp Anticorpo para tigit, seu uso e método para produzir o mesmo
JP7122354B2 (ja) * 2019-09-24 2022-08-19 財團法人工業技術研究院 抗ｔｉｇｉｔ抗体および使用方法
CN114746446A (zh) * 2019-11-21 2022-07-12 百济神州有限公司 使用抗ox40抗体与抗tigit抗体组合治疗癌症的方法
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
CN113563470B (zh) * 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
WO2021258337A1 (en) * 2020-06-24 2021-12-30 Huahui Health Ltd. Human monoclonal antibodies against tigit for immune related diseases
CA3194641A1 (en) * 2020-10-26 2022-05-05 Akeso Biopharma, Inc. Anti-tigit antibody, and pharmaceutical composition and use thereof
WO2022111612A1 (zh) * 2020-11-26 2022-06-02 信达生物制药(苏州)有限公司 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途
CN114539418A (zh) * 2020-11-26 2022-05-27 上海华奥泰生物药业股份有限公司 双特异性抗体及其用途
EP4293045A4 (en) * 2021-01-14 2024-12-11 Shanghai Junshi Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION OF ANTI-TIGIT ANTIBODY AND ITS APPLICATION
CN114790241B (zh) * 2021-01-26 2024-12-13 北京免疫方舟医药科技有限公司 抗tigit抗体及其应用
CN112794909B (zh) * 2021-02-04 2022-06-14 广州爱思迈生物医药科技有限公司 一种抗tigit单克隆抗体及其应用
WO2022179567A1 (zh) * 2021-02-24 2022-09-01 克莱格医学有限公司 Tigit工程化细胞及其组合物
CN114984227A (zh) * 2021-03-02 2022-09-02 百奥泰生物制药股份有限公司 抗tigit抗体在联合用药中的应用
CN114989300A (zh) * 2021-03-02 2022-09-02 百奥泰生物制药股份有限公司 抗tigit抗体在治疗肿瘤或癌症中的应用
CN113150156B (zh) * 2021-04-22 2022-06-07 浙江博锐生物制药有限公司 抗tigit抗体及其用途
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CA3219603A1 (en) * 2021-05-10 2022-11-17 Medimabbio Inc. Anti-tigit antibodies and use thereof
EP4386003A1 (en) * 2021-08-09 2024-06-19 Biotheus Inc. Anti-tigit antibody and use thereof
CN115838424A (zh) * 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
CN115925945A (zh) * 2021-09-24 2023-04-07 广东菲鹏制药股份有限公司 抗tigit人源化抗体或其抗原结合片段及其应用
CN116135884A (zh) * 2021-11-17 2023-05-19 普米斯生物技术(珠海)有限公司 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
CN116143923B (zh) * 2022-12-30 2025-11-11 合肥天港免疫药物有限公司 高亲和力tigit抗体及其应用
WO2024251140A1 (en) * 2023-06-06 2024-12-12 Wuxi Biologics (Shanghai) Co., Ltd. Anti-tigit antibodies and uses thereof
CN119285774A (zh) * 2023-10-11 2025-01-10 首都医科大学附属北京胸科医院 抗人tigit单克隆抗体tigit-m007或其功能性片段及其应用
CN119431580B (zh) * 2024-09-29 2025-11-18 上海百英生物科技股份有限公司 一种抗人tigit单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016028656A1 (en) * 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2016106302A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
WO2016191643A2 (en) 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
ES2357505T3 (es) 2002-09-11 2011-04-27 Genentech, Inc. Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas.
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
EP1963534A2 (en) 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
MX2010011088A (es) 2008-04-09 2010-11-05 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
CA2755782A1 (en) 2009-03-18 2010-09-23 Simon Barry Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t 9treg) cells and uses therefor
EP2388336A1 (en) 2010-05-19 2011-11-23 Signature Diagnostics AG Method and kits for diagnosing colorectal cancer
US8822642B2 (en) 2010-06-09 2014-09-02 Zymogenetics, Inc. Dimeric fusion proteins and related compositions and methods
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
WO2013184912A2 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
DK2925350T3 (da) 2012-12-03 2019-05-13 Bristol Myers Squibb Co Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂，其制备方法和用途
DK3021869T3 (da) * 2013-07-16 2020-09-21 Hoffmann La Roche Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere
WO2016011264A1 (en) 2014-07-16 2016-01-21 Genentech, Inc. Methods of treating cancer using tigit inhibitors and anti-cancer agents
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US10766957B2 (en) * 2015-08-14 2020-09-08 Merck Sharp & Dohme Corp Anti-TIGIT antibodies
EP3353210B8 (en) 2015-09-25 2024-12-18 F. Hoffmann-La Roche AG Anti-tigit antibodies and methods of use
SG10201912736UA (en) 2015-10-01 2020-02-27 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
IL261188B (en) * 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
MA47694A (fr) * 2017-02-28 2021-05-19 Seagen Inc Anticorps anti-tigit
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
IL272227B2 (en) 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
SG11202011461TA (en) * 2018-06-01 2020-12-30 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
CN113993894B (zh) * 2019-01-07 2024-08-02 Iteos比利时公司 抗tigit抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016028656A1 (en) * 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2016106302A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
WO2016191643A2 (en) 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof

Also Published As

Publication number Publication date
MX2020000960A (es) 2020-07-22
IL272227A (en) 2020-03-31
AU2018306463B2 (en) 2025-03-27
CN110997720A (zh) 2020-04-10
JP2020528768A (ja) 2020-10-01
KR20200100589A (ko) 2020-08-26
AR112768A1 (es) 2019-12-11
EP3484925A1 (en) 2019-05-22
US20200407445A1 (en) 2020-12-31
IL272227B2 (en) 2025-09-01
US20230190931A1 (en) 2023-06-22
JP7366897B2 (ja) 2023-10-23
EP3719040A1 (en) 2020-10-07
JP2023153911A (ja) 2023-10-18
SG11202000660QA (en) 2020-02-27
CN110997720B (zh) 2024-10-01
AU2018306463A1 (en) 2020-03-05
EP3484925B1 (en) 2020-05-27
BR112020001499A2 (pt) 2020-09-08
US20230181731A1 (en) 2023-06-15
IL272227B1 (en) 2025-05-01
MX2024000742A (es) 2024-02-09
US10329349B2 (en) 2019-06-25
CN119841950A (zh) 2025-04-18
TWI812632B (zh) 2023-08-21
CA3070791A1 (en) 2019-01-31
TW201910351A (zh) 2019-03-16
US11439705B2 (en) 2022-09-13
ES2812236T3 (es) 2021-03-16
US20190100591A1 (en) 2019-04-04
US20190315867A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
KR102731476B1 (ko) 항-tigit 항체
WO2019023504A1 (en) ANTI-TIGIT ANTIBODIES
JP7512290B2 (ja) 抗ｔｉｇｉｔ抗体
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
JP2022502052A (ja) 抗ｈｌａ−ｇ抗体、抗ｈｌａ−ｇ抗体を含む組成物、および抗ｈｌａ−ｇ抗体を使用する方法
EP3356413A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
CN114401992A (zh) 结合igsf11（vsig3）的igc2的抗体及其用途
RU2819624C2 (ru) Композиции анти-cd112r антител и сопутствующие способы
EA045372B1 (ru) Анти-tigit антитела
HK40027182A (en) Anti-tigit antibodies
HK40027182B (zh) 抗tigit抗体
RU2771964C2 (ru) Антитела против сигнал-регуляторного белка альфа и способы их применения
BE1025333B1 (fr) Anticorps anti-tigit

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210723

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240116

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240903

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241113

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241113

End annual number: 3

Start annual number: 1

PG1601 Publication of registration